Monte Rosa CSO trades 3,000 shares in planned sale

Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson exercised options for 3,000 shares of common stock at $6.14 per share and on the same day sold 3,000 shares at $19.00 per share in an open-market transaction.

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson exercised options for 3,000 shares of common stock at $6.14 per share and on the same day sold 3,000 shares at $19.00 per share in an open-market transaction. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following the sale, Townson directly holds 67,845 common shares, along with 206,290 stock options that remain outstanding.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,000 shares ($39K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Townson Sharon

Role Chief Scientific Officer

Sold 3,000 shs ($57K)

Approx. gross sale proceeds $57K

Approx. exercise cost $18K

Approx. pre-tax spread $39K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	$0.00
Exercise	Common Stock	3,000	$6.14	$18K
Sale	Common Stock	3,000	$19.00	$57K

Holdings After Transaction: Stock Option (Right to Buy) — 206,290 contracts (Direct); Common Stock — 67,845 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
2. F2. This option is fully vested and exercisable.

Key Figures

Shares sold: 3,000 shares Sale price: $19.00 per share Options exercised: 3,000 shares +3 more

6 metrics

Shares sold 3,000 shares Open-market sale of common stock on June 17, 2026

Sale price $19.00 per share Price for 3,000 common shares sold

Options exercised 3,000 shares Stock options converted into common shares on June 17, 2026

Option exercise price $6.14 per share Strike price for exercised stock options

Common shares held after 67,845 shares Direct non-derivative holdings following transactions

Options outstanding after 206,290 options Derivative holdings following reported exercise

Key Terms

Rule 10b5-1 trading plan, open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for the 3,000-share common stock transaction."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" describes the option exercises reported."

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for the derivative security exercised."

fully vested and exercisable financial

"This option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Monte Rosa Therapeutics (GLUE) CSO Sharon Townson do in this Form 4?

Sharon Townson exercised stock options for 3,000 Monte Rosa Therapeutics shares and sold 3,000 shares in an open-market transaction. Both actions occurred on the same date and were part of a disclosed trading plan.

How many Monte Rosa Therapeutics (GLUE) shares did the CSO sell and at what price?

Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics common stock at $19.00 per share. The transaction is classified as an open-market sale and is reported as a non-derivative transaction in the filing.

What stock options did the Monte Rosa Therapeutics (GLUE) CSO exercise?

Townson exercised stock options covering 3,000 shares of Monte Rosa Therapeutics common stock at an exercise price of $6.14 per share. The options are fully vested and exercisable, according to the filing footnotes.

How many Monte Rosa Therapeutics (GLUE) shares does the CSO own after these transactions?

After the reported transactions, Sharon Townson directly holds 67,845 shares of Monte Rosa Therapeutics common stock. This figure reflects her direct non-derivative ownership following the option exercise and same-day sale.

Were the GLUE insider transactions made under a Rule 10b5-1 trading plan?

Yes, the filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on February 27, 2026. Such plans pre-schedule trades, making their timing more routine and less discretionary.

What derivative holdings remain for the Monte Rosa Therapeutics (GLUE) CSO?

Following the option exercise, Townson has 206,290 stock options reported as outstanding. These options relate to rights to buy Monte Rosa Therapeutics common stock under previously granted equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townson Sharon

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		M(1)		3,000	A	$6.14	70,845	D
Common Stock	06/17/2026		S(1)		3,000	D	$19	67,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	06/17/2026		M(1)			3,000	(2)	04/12/2031	Common Stock	3,000	$0	206,290	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. This option is fully vested and exercisable.

	/s/ Phil Nickson, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)